Skip to content

Systemic lupus erythematosus

Two EULAR documents: the 2023 general SLE update and the 2025 update for SLE with kidney involvement, which replaces the nephritis recommendations of 2023 and the 2019 EULAR/ERA-EDTA guideline.

EULAR SLE 2023

International Current

EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

Official source

EULAR lupus nephritis 2025

International Current

EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

Official source

Clinical pearls

  • Hydroxychloroquine for every patient, unless contraindicated, at ≤5 mg/kg/day.
  • Steroids ≤5 mg/day prednisone for maintenance, and stop if possible.
  • Biologics: belimumab (anti-BAFF) and anifrolumab (anti-type I interferon receptor) for active extrarenal disease; belimumab, voclosporin and obinutuzumab for nephritis.
  • Lupus nephritis: biopsy at proteinuria ≥0.5 g/day; combination therapy first; continue ≥3 years.
  • Thrombotic APS: warfarin.